Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Sponsor: Accelerating Medicines Partnership (AMP)
A PHASE2/PHASE3 clinical study on Alzheimers Disease and Alzheimers Disease, Familial, this trial is ongoing. The trial is conducted by Accelerating Medicines Partnership (AMP) and has accumulated 28 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
28 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2/PHASE3
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 23 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2023 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2022 — May 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2021 — Dec 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Completed → Recruiting
-
Sep 2020 — Nov 2020 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
May 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2019 — May 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Active Not Recruiting → Recruiting
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Active Not Recruiting → Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Accelerating Medicines Partnership (AMP)
- Alzheimer's Association
- Avid Radiopharmaceuticals
- Eisai Inc.
- Eli Lilly and Company
- Hoffmann-La Roche
- Janssen, LP
- National Institute on Aging (NIA)
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .